| Symbol
| LGALS9
| contributors: mct - updated : 02-02-2017
|
| HGNC name
| lectin, galactoside-binding, soluble, 9
|
| HGNC id
| 6570
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
| insertion
|
|
| |
in colorectal cancer | | constitutional
|
|
| --low
|
| |
in end-stage dilated cardiomyopathy (Colak 2009) | | tumoral
|
|
| --over
|
| |
overexpressed in Hodgkin's disease tissue | | tumoral
|
|
| --low
|
|
is a predictor of worse prognosis in pancreatic cancer patients  | |
Variant & Polymorphism
| 
| |
| Candidate gene
| LGALS9-induced apoptosis of hyperproliferative rheumatoid arthritis (RA) fibroblast-like synoviocytes may play a role in the suppression of RA (Seki 2007) |
|
decreased LGALS9 expression is inversely associated with malignant potential or differentiation of cervical intraepithelial neoplasia and cervical squamous cell carcinoma as a differentiation biomarker (Liang 2008) |
Marker
| Therapy target
| may have a beneficial utility fir the treatment of allergic disorders including asthma (Niki 2009) | |
blocking LGALS9-HAVCR2 interaction in vivo might alleviate the Th1-suppressive effect of NPC exosomes and sustain antitumoral T-cell responses and thereby improve clinical efficacy of immunotherapeutic approaches against nasopharyngeal carcinoma (Klibi 2009) | |
| |